Roche Enters $7.1 Billion Deal to Acquire Telavant
Swiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreSwiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreStressMarq manufactures and offers a wide range of products specifically developed to accelerate Parkinson’s disease research. StressMarq’s cutting-edge product range
Read moreIn a recent scientific commentary, Brenda Knox at StressMarq delves into the complex interplay between amyloid-beta plaques and tau neurofibrillary
Read moreStressMarq Biosciences, a prominent leader in the field of neurodegenerative disease research products, is excited to announce its participation in
Read moreResearchers have devised a novel human 3D model for Alzheimer’s Disease, enabling the study of immune cell involvement in the
Read moreGSK plc has unveiled entering into a strategic collaboration with Chongqing Zhifei Biological Products, Ltd. (Zhifei), marking a pivotal move
Read moreModerna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, has unveiled
Read moreThe Biosimilar Tyruko® has been approved for all indications of reference medicine, as the first and only biosimilar to treat
Read more